327 related articles for article (PubMed ID: 29327492)
1. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
[TBL] [Abstract][Full Text] [Related]
2. Identification of Key Biomarkers and Potential Molecular Mechanisms in Renal Cell Carcinoma by Bioinformatics Analysis.
Li F; Guo P; Dong K; Guo P; Wang H; Lv X
J Comput Biol; 2019 Nov; 26(11):1278-1295. PubMed ID: 31233342
[No Abstract] [Full Text] [Related]
3. Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer.
Yang J
Med Oncol; 2020 Mar; 37(5):34. PubMed ID: 32219571
[TBL] [Abstract][Full Text] [Related]
4. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
5. Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma.
Li Q; Yang W; Lu M; Zhang R
Med Sci Monit; 2020 Dec; 26():e927078. PubMed ID: 33296352
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
7. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
8. CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Oct; 41(10):4875-4883. PubMed ID: 34593435
[TBL] [Abstract][Full Text] [Related]
9. Characterization and function of biomarkers in sunitinib-resistant renal carcinoma cells.
Wang YL; Liu H; Wan LL; Pan KH; Ni JX; Hu Q; Bin X; Chen M
Gene; 2022 Jul; 832():146514. PubMed ID: 35550407
[TBL] [Abstract][Full Text] [Related]
10. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
11. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
12. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
14. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
15. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
Chen L; Lu D; Sun K; Xu Y; Hu P; Li X; Xu F
Gene; 2019 Apr; 692():119-125. PubMed ID: 30654001
[TBL] [Abstract][Full Text] [Related]
16. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.
Wang C; Li Y; Chu CM; Zhang XM; Ma J; Huang H; Wang YN; Hong TY; Zhang J; Pan XW; Zheng JC; Jiang N; Hu CY; Ma X; Sun YH; Cui XG
EBioMedicine; 2019 Jan; 39():255-264. PubMed ID: 30558998
[TBL] [Abstract][Full Text] [Related]
17. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
18. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract][Full Text] [Related]
19. A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma.
Li F; Hu W; Zhang W; Li G; Guo Y
Dis Markers; 2020; 2020():8352809. PubMed ID: 32184905
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.
Rini BI; Escudier B; Martini JF; Magheli A; Svedman C; Lopatin M; Knezevic D; Goddard AD; Febbo PG; Li R; Lin X; Valota O; Staehler M; Motzer RJ; Ravaud A
Clin Cancer Res; 2018 Sep; 24(18):4407-4415. PubMed ID: 29773662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
